Head-to-head evidence
Camrelizumab vs Penpulimab
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: PD-1 · full Non-Small Cell Lung Cancer pipeline
Camrelizumab
Developed by Jiangsu Hengrui Pharmaceuticals
NCT03134872 · Phase 3 · completed
The study randomly assigned 419 participants to treatment or an active chemotherapy comparator, but it was open-label rather than blinded. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Penpulimab
Marketed by Akeso
NCT03866993 · Phase 3 · completed
This randomized, placebo-controlled trial kept participants, care providers, investigators and outcome assessors blind to treatment assignment, with disease progression assessed by an independent radiology committee. Its primary endpoint, progression-free survival, was clearly met, roughly doubling median progression-free survival versus placebo plus chemotherapy.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Camrelizumab's landscape · Penpulimab's landscape